The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Mar 18

PMID 32180772

Citations 16

Authors

Elisa Wirthgen

Anne K Leonard

Christian Scharf

Grazyna Domanska

Affiliations

Soon will be listed here.

Abstract

Animal model studies revealed that the application of 1-methyltryptophan (1-MT), a tryptophan (TRP) analog, surprisingly increased plasma levels of the TRP metabolite, kynurenic acid (KYNA). Under inflammatory conditions, KYNA has been shown to mediate various immunomodulatory effects. Therefore, the present study aims to confirm and clarify the effects of 1-MT on TRP metabolism in mice as well as in humans. Splenocytes from Balb/C or indoleamine 2,3-dioxygenase knockout () mice or whole human blood were stimulated with 1-MT for 6, 24, or 36 h. C57BL/6 mice received 1-MT in drinking water for 5 days. Cell-free supernatants and plasma were analyzed for TRP and its metabolites by tandem mass spectrometry (MS/MS). 1-MT treatment induced an increase in TRP and its metabolite, KYNA in Balb/C, mice, and in human blood. Concurrently, the intermediate metabolite kynurenine (KYN), as well as the KYN/TRP ratio, were reduced after 1-MT treatment. The effects of 1-MT on TRP metabolites were similar after the application of 1-MT to C57BL/6 mice. The data indicate that 1-MT induced an increase of KYNA and confirming previously described results. Furthermore, the results of mice indicate that this effect seems not to be mediated by IDO1. Due to the proven immunomodulatory properties of KYNA, a shift toward this branch of the kynurenine pathway (KP) may be one potential mode of action by 1-MT and should be considered for further applications.

Citing Articles

effect of 1-methyltryptophan isomers on epithelial-mesenchymal transition transcription factors in tubular epithelial cells after ischemia-reperfusion injury.

Ali NejadKasbakhi N, Vavrincova D, cepcova D Arch Razi Inst. 2024; 79(2):307-314.

PMID: 39463718 PMC: 11512173. DOI: 10.32592/ARI.2024.79.2.307.

Tryptophan Metabolism Disorder-Triggered Diseases, Mechanisms, and Therapeutic Strategies: A Scientometric Review.

Chen X, Xu D, Yu J, Song X, Li X, Cui Y Nutrients. 2024; 16(19).

PMID: 39408347 PMC: 11478743. DOI: 10.3390/nu16193380.

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders.

Mor A, Tankiewicz-Kwedlo A, Ciwun M, Lewkowicz J, Pawlak D Cells. 2024; 13(15.

PMID: 39120289 PMC: 11311768. DOI: 10.3390/cells13151259.

knock-out parasites reprogram tryptophan metabolism to induce a pro-inflammatory response.

Oljuskin T, Azodi N, Volpedo G, Bhattacharya P, Markle H, Hamano S iScience. 2023; 26(9):107593.

PMID: 37744403 PMC: 10517402. DOI: 10.1016/j.isci.2023.107593.

Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin.

Corrigan M, ORourke A, Moran B, Fletcher J, Harkin A Neuronal Signal. 2023; 7(2):NS20220054.

PMID: 37457896 PMC: 10345431. DOI: 10.1042/NS20220054.

References

Wirthgen E, Tuchscherer M, Otten W, Domanska G, Wollenhaupt K, Tuchscherer A . Activation of indoleamine 2,3-dioxygenase by LPS in a porcine model. Innate Immun. 2013; 20(1):30-9. DOI: 10.1177/1753425913481252. View

Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R . IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis. PLoS One. 2016; 11(2):e0150075. PMC: 4767214. DOI: 10.1371/journal.pone.0150075. View

Cady S, Sono M . 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys. 1991; 291(2):326-33. DOI: 10.1016/0003-9861(91)90142-6. View

Liu X, Newton R, Friedman S, Scherle P . Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets. 2009; 9(8):938-52. DOI: 10.2174/156800909790192374. View

Jia L, Schweikart K, Tomaszewski J, Page J, Noker P, Buhrow S . Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol. 2007; 46(1):203-11. PMC: 2744343. DOI: 10.1016/j.fct.2007.07.017. View

Lob S, Konigsrainer A, Zieker D, Brucher B, Rammensee H, Opelz G . IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2008; 58(1):153-7. PMC: 11030193. DOI: 10.1007/s00262-008-0513-6. View

Metz R, Rust S, DuHadaway J, Mautino M, Munn D, Vahanian N . IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012; 1(9):1460-1468. PMC: 3525601. DOI: 10.4161/onci.21716. View

Liu X, Shin N, Koblish H, Yang G, Wang Q, Wang K . Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010; 115(17):3520-30. DOI: 10.1182/blood-2009-09-246124. View

Kanai M, Nakamura T, Funakoshi H . Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res. 2009; 64(1):111-7. DOI: 10.1016/j.neures.2009.02.004. View

10.

Gunther J, Dabritz J, Wirthgen E . Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment. Front Immunol. 2019; 10:1801. PMC: 6682646. DOI: 10.3389/fimmu.2019.01801. View

11.

Moroni F, Cozzi A, Sili M, Mannaioni G . Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm (Vienna). 2012; 119(2):133-9. DOI: 10.1007/s00702-011-0763-x. View

12.

Han Q, Cai T, Tagle D, Robinson H, Li J . Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep. 2008; 28(4):205-15. PMC: 2559858. DOI: 10.1042/BSR20080085. View

13.

Wirthgen E, Kanitz E, Tuchscherer M, Tuchscherer A, Domanska G, Weitschies W . Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model. Exp Anim. 2016; 65(2):147-55. PMC: 4873483. DOI: 10.1538/expanim.15-0096. View

14.

Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H . Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006; 281(31):22021-22028. DOI: 10.1074/jbc.M603503200. View

15.

Schmidt S, Siepmann S, Kuhlmann K, Meyer H, Metzger S, Pudelko S . Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase. PLoS One. 2012; 7(9):e44797. PMC: 3441469. DOI: 10.1371/journal.pone.0044797. View

16.

Tiszlavicz Z, Nemeth B, Fulop F, Vecsei L, Tapai K, Ocsovszky I . Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383(5):447-55. DOI: 10.1007/s00210-011-0605-2. View

17.

Elizei S, Poormasjedi-Meibod M, Wang X, Kheirandish M, Ghahary A . Kynurenic acid downregulates IL-17/1L-23 axis in vitro. Mol Cell Biochem. 2017; 431(1-2):55-65. DOI: 10.1007/s11010-017-2975-3. View

18.

Divanovic S, Sawtell N, Trompette A, Warning J, Dias A, Cooper A . Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis. 2011; 205(1):152-61. PMC: 3242739. DOI: 10.1093/infdis/jir621. View

19.

Gaffen S, Jain R, Garg A, Cua D . The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9):585-600. PMC: 4281037. DOI: 10.1038/nri3707. View

20.

Steiner L, Gold M, Mengel D, Dodel R, Bach J . The endogenous α7 nicotinic acetylcholine receptor antagonist kynurenic acid modulates amyloid-β-induced inflammation in BV-2 microglial cells. J Neurol Sci. 2014; 344(1-2):94-9. DOI: 10.1016/j.jns.2014.06.032. View